Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine

Simple Summary Early diagnosis of renal cell carcinoma (RCC) is challenging and typically incidental. Currently, several therapeutic strategies are used for the treatment; however, no established predictive biomarker has been established yet, and the optimal treatment choice and sequence of use remain unclear. Moreover, the recurrence occurs in about one-third of patients after tumor resection. Although several prognostic classification systems have been proposed, most of them showed only limited potential in recurrence prediction. Therefore, identifying simple, reliable, and easily accessible biomarkers to anticipate the diagnosis, effectively evaluate the risk of relapse, and predict the response to the therapeutic regimens is an unmet clinical need. Circulating cell-free DNA (cfDNA), released from cancer cells into the bloodstream, was shown to be a non-invasive, viable, inexpensive method to diagnose and monitor several solid malignancies, designed as a potential blood RCC biomarker. This review aims to summarize the state of the art of the current genetic and epigenetic techniques of plasma and serum cfDNA detection and outline the potential application of liquid biopsy in RCC. Abstract Tumor biopsy is still the gold standard for diagnosing and prognosis renal cell carcinoma (RCC). However, its invasiveness, costs, and inability to accurately picture tumor heterogeneity represent major limitations to this procedure. Analysis of circulating cell-free DNA (cfDNA) is a non-invasive cost-effective technique that has the potential to ease cancer detection and prognosis. In particular, a growing body of evidence suggests that cfDNA could be a complementary tool to identify and prognosticate RCC while providing contemporary mutational profiling of the tumor. Further, recent research highlighted the role of cfDNA methylation profiling as a novel method for cancer detection and tissue-origin identification. This review synthesizes current knowledge on the diagnostic, prognostic, and predictive applications of cfDNA in RCC, with a specific focus on the potential role of cell-free methylated DNA (cfMeDNA).

[1]  F. Massari,et al.  Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors. , 2022, European urology focus.

[2]  P. Ferrari,et al.  Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC , 2022, International journal of molecular sciences.

[3]  Abhijit A. Patel,et al.  Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics , 2022, Nature Biomedical Engineering.

[4]  D. Brenner,et al.  Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis , 2022, European urology open science.

[5]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[6]  R. Danesi,et al.  Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management. , 2022, Pharmacogenomics.

[7]  F. Massari,et al.  Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma , 2021, Targeted Oncology.

[8]  M. Miccoli,et al.  Is it time to consider the Androgen receptor as a therapeutic target in breast cancer? , 2021, Anti-cancer agents in medicinal chemistry.

[9]  M. Miccoli,et al.  Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients , 2021, Journal of clinical medicine.

[10]  K. Aldape,et al.  DNA Methylation based prognostic subtypes of chordoma tumors in tissue and plasma. , 2021, Neuro-oncology.

[11]  C. Criscitiello,et al.  Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. , 2021, Histology and histopathology.

[12]  D. Gandara,et al.  Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer , 2021, Expert review of molecular diagnostics.

[13]  C. Mazzanti,et al.  Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapy , 2021, Investigational New Drugs.

[14]  F. Sotgia,et al.  New insights in the expression of stromal caveolin 1 in breast cancer spread to axillary lymph nodes , 2021, Scientific Reports.

[15]  L. Muinelo-Romay,et al.  Circulating Free DNA and Its Emerging Role in Autoimmune Diseases , 2021, Journal of personalized medicine.

[16]  Lixin Yang,et al.  Circulating tumor DNA analysis of metastatic renal cell carcinoma , 2020, Molecular and clinical oncology.

[17]  M. Loda,et al.  Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum , 2020, Molecular Cancer Research.

[18]  N. Lindeman,et al.  Intestinal metaplasia of the urinary tract harbors potentially oncogenic genetic variants , 2020, Modern Pathology.

[19]  K. Aldape,et al.  Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes , 2020, Nature Medicine.

[20]  Keegan D. Korthauer,et al.  Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes , 2020, Nature Medicine.

[21]  N. Rosenfeld,et al.  ctDNA monitoring using patient-specific sequencing and integration of variant reads , 2020, Science Translational Medicine.

[22]  C. Andersen,et al.  The effect of surgical trauma on circulating free DNA levels in cancer patients—implications for studies of circulating tumor DNA , 2020, Molecular oncology.

[23]  A. Shinagare,et al.  Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma , 2020, Genetics in Medicine.

[24]  G. Fanelli,et al.  Recent Advances in Cancer Plasticity: Cellular Mechanisms, Surveillance Strategies, and Therapeutic Optimization , 2020, Frontiers in Oncology.

[25]  D. Berry,et al.  Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  N. Rosenfeld,et al.  Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors , 2020, Genome Medicine.

[27]  M. Gleave,et al.  Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. , 2020, Clinical genitourinary cancer.

[28]  S. Bratman,et al.  Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA , 2019, Nature Protocols.

[29]  D. Bourc’his,et al.  The diverse roles of DNA methylation in mammalian development and disease , 2019, Nature Reviews Molecular Cell Biology.

[30]  M. Fassan,et al.  Thyroid-like follicular carcinoma of the kidney: The mutational profiling reveals a BRAF wild type status. , 2019, Pathology, research and practice.

[31]  G. Spolverato,et al.  Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases , 2019, British Journal of Cancer.

[32]  T. van der Poll,et al.  Systemic inflammation induces release of cell-free DNA from hematopoietic and parenchymal cells in mice and humans. , 2019, Blood advances.

[33]  Rajat Singhania,et al.  Sensitive tumour detection and classification using plasma cell-free DNA methylomes , 2018, Nature.

[34]  Keval Patel,et al.  Enhanced detection of circulating tumor DNA by fragment size analysis , 2018, Science Translational Medicine.

[35]  Brittany N. Lasseigne,et al.  The Role of DNA Methylation in Renal Cell Carcinoma , 2018, Molecular Diagnosis & Therapy.

[36]  M. Rugge,et al.  MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. , 2018, Pathology, research and practice.

[37]  N. Nonomura,et al.  Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma , 2018, Oncotarget.

[38]  Abhijit A. Patel,et al.  Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA , 2018, Clinical Cancer Research.

[39]  S. Mortimer,et al.  The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients , 2017, Clinical Cancer Research.

[40]  M. Fassan,et al.  Noncoding RNAs as drivers of the phenotypic plasticity of oesophageal mucosa , 2017, World journal of gastroenterology.

[41]  S. Signoretti,et al.  Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. , 2017, European urology.

[42]  A. Douvdevani,et al.  Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma , 2017, Oncology Research and Treatment.

[43]  Sam Angiuoli,et al.  Direct detection of early-stage cancers using circulating tumor DNA , 2017, Science Translational Medicine.

[44]  S. Pal,et al.  Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden , 2017, Kidney cancer.

[45]  N. Agarwal,et al.  Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications , 2017, Oncotarget.

[46]  H. Moch,et al.  Detecting circulating tumor DNA in renal cancer: An open challenge. , 2017, Experimental and molecular pathology.

[47]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[48]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[49]  Mark Lee,et al.  Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection , 2017, Cell.

[50]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Oleksii Nikolaienko,et al.  Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer , 2016, Disease markers.

[52]  Howard Cedar,et al.  DNA Methylation in Cancer and Aging. , 2016, Cancer research.

[53]  F. Boccardo,et al.  The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome , 2016, BMC Cancer.

[54]  K. Jung,et al.  Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[55]  A. Nicholson,et al.  Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. , 2015, Clinical chemistry.

[56]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[57]  Michael Q. Zhang,et al.  Integrative analysis of 111 reference human epigenomes , 2015, Nature.

[58]  F. Boccardo,et al.  Periostin: a novel prognostic and therapeutic target for genitourinary cancer? , 2014, Clinical genitourinary cancer.

[59]  Franck Molina,et al.  Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA , 2014, Nature Medicine.

[60]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[61]  Antonio C. Wolff,et al.  Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer , 2014, Clinical Cancer Research.

[62]  J. Ellinger,et al.  Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. , 2013, Anticancer research.

[63]  Eric-Wubbo Lameijer,et al.  Identification and systematic annotation of tissue-specific differentially methylated regions using the Illumina 450k array , 2013, Epigenetics & Chromatin.

[64]  K. Cheng,et al.  Monitoring of Plasma Cell-Free DNA in Predicting Postoperative Recurrence of Clear Cell Renal Cell Carcinoma , 2013, Urologia Internationalis.

[65]  Guorong Li,et al.  Quantification of Plasma Cell-Free DNA1 in Predicting Therapeutic Efficacy of Sorafenib on Metastatic Clear Cell Renal Cell Carcinoma , 2013, Disease markers.

[66]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[67]  Ben H. Park,et al.  Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.

[68]  T. Klatte,et al.  Serum cell‐free DNA in renal cell carcinoma , 2012, Cancer.

[69]  Jeff Mellen,et al.  High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.

[70]  Kikuya Kato,et al.  Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.

[71]  T. Glenn.  Field guide to next‐generation DNA sequencers , 2011, Molecular ecology resources.

[72]  J. Ellinger,et al.  Cell-free circulating DNA: Diagnostic value in patients with renal cell cancer. , 2010, Anticancer research.

[73]  Zhao An,et al.  Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. , 2010, Urology.

[74]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[75]  L. Kavoussi,et al.  Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. , 2009, The Journal of urology.

[76]  E. Fasoli,et al.  Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. , 2008, European journal of cancer.

[77]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[78]  P. Russo,et al.  Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Frank Diehl,et al.  BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions , 2006, Nature Methods.

[80]  B. Konety.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system , 2006 .

[81]  G. Einarsson,et al.  Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. , 2005, Urology.

[82]  J. Lam,et al.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. , 2005, The Journal of urology.

[83]  J. Califano,et al.  Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer , 2004, Cancer Research.

[84]  G. Israel,et al.  Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. , 2004, Radiology.

[85]  B. Trock,et al.  Prognostic significance of preoperative molecular serum analysis in renal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  T. Kälble,et al.  High frequency of serum DNA alterations in renal cell carcinoma detected by fluorescent microsatellite analysis , 2002, International journal of cancer.

[87]  F. Marshall,et al.  Diagnosis of Renal Cancer by Molecular Urinalysis , 1999 .

[88]  K. Miller,et al.  Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. , 1998, Cancer research.

[89]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.